Objectives & outcomes:
Patient-level analytics:
- Immune and stromal cell population estimation for an individual patient
Cohort-level analytics:
- Quantification and analysis of immune-related signature scores
- Identification of immune-related differentially expressed genes (IR-DEGs)
- Immunomodulators and cytokine expression profiles
- Immune-related pathway enrichment analysis
- Prognostic immune signature (PIS) identification and patient stratification
Salient features:
- Provides a single platform for characterizing the TME at the cellular and molecular level
- Enables characterization of immune and stromal cell profiles for the individual patient
- Allows quantification and identification of various immune-related signatures which have immunotherapeutic as well as prognostic significance
- Helps in understanding tumor immunogenicity and its impact on treatment strategies, particularly in the case of immunotherapy
Demo use case: Breast cancer
Data source: The Cancer Genome Atlas
Business model: Contract services
Please write to us:
for details & we will be happy to discuss: timecartbd@citadelpm.io
